Swedish-based pharmaceutical company Camurus has concluded the Phase II study of CAM2029 to treat acromegaly or neuroendocrine tumours (NETs).

Developed in collaboration with Novartis, CAM2029 is an octreotide subcutaneous product featuring FluidCrystal formulation that can be self applied by patients as a ready-to-use injection in a pre-filled syringe supported with a needle stick safety device.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It is intended to be used as an alternative to the existing, long-acting somatostatin analogue formulations.

The phase II trial is an open-label, multicentre, randomised study that involved 12 adult patients.

"The company is currently preparing for a Phase III clinical trial of CAM2029 in association with Novartis and is expected to start next year."

It was designed to evaluate the pharmacodynamics and pharmacokinetics profile, as well as the safety and efficacy of two dosing regimens of CAM2029.

See Also:

Results have displayed therapeutic blood-levels of octreotide over four weeks.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial has also demonstrated a consistent safety and local tolerability of CAM2029 across the study.

Camurus president and CEO Fredrik Tiberg said: "The positive pharmacokinetic profile and promising disease control data seen in this Phase II study when switching patients from Sandostatin LAR to CAM2029, together with the option for self-administration by patients, underscores the potential for CAM2029 to fill an unmet medical need."

The company is currently preparing for a Phase III clinical trial of CAM2029 in association with Novartis and is expected to start next year.